+ Treatment Action Campaign

SECTION27, TAC, YN, EE, welcomes HCT for teens but cautions on approach

We support implementation of a programme of HIV Counselling and Testing (HCT) for Teens … but proper planning and protection of human rights of learners is essential.

The Treatment Action Campaign (TAC), The Yezingane Network (YN) , Equal Education and SECTION27 welcome the Department of Health’s plans to extend HIV Counselling and Testing (HCT) campaign to children 12 years and older.

ASA rules against Christ Embassy

TAC will call on ETV to stop airing their adverts in current form
Join the TAC press conference at 1pm Thursday 3 February, 3rd Floor 122 Longmarket Street, Cape Town.

SECTION27 and TAC applaud successful ARV medicine tender

SECTION27 and TAC applauds the successful ARV medicine tender – but call for continued actions to drive prices of essential medicines down further.

SECTION27 and TAC applaud the Minister of Health and his team at the Department of Health (DoH) for their part in conceptualising, implementing and concluding a successful antiretroviral (ARV) medicine tender. Announced yesterday, the 2010 tender – for the period 1 January 2011 to 31 December 2012 – will see the state procuring ARV medicines at or about the best prices available globally.

Study proves that a pill a day reduces the risk of HIV infection amongst men who have sex with men

SECTION27 and the Treatment Action Campaign (TAC) welcome the results of the Pre-exposure Prophylaxis Initiative (iPrEX) trial. Published yesterday in the New England Journal of Medicine (NEJM), the study is the first to establish that pre-exposure prophylaxis (PrEP) – taking antiretroviral (ARV) medicines before sex – reduces the risk of HIV infection. It follows closely on the heels of the CAPRISA 004 trial, which demonstrated that the use of tenofovir 1% gel reduced the risk of HIV infection amongst women at increased risk.

The iPrEx trial enrolled 2499 men who have sex with men (MSM) at 11 sites across the world (including Cape Town). Half of the trial participants were randomly assigned to take a daily dose of two ARV medicines – tenofovir disproxil fumarate (TDF) and emtricitabine (FTC) – combined into a single pill. The other half, also randomly assigned, received a daily placebo. All received a comprehensive package of HIV prevention services, including regular HIV testing, risk-reduction counselling, condoms, and the treatment of symptomatic sexually transmitted infections.

Health Department allows patients to get three months of antiretroviral treatment

The Department of Health has given the go-ahead for patients on antiretroviral treatment (ART) to be given three months supply of medicines instead of one month. The TAC and SECTION27 welcome this decision. It will be more convenient for patients because they will have to make fewer trips to their health facility. It will also reduce patient-load on the health system, particularly on health facility pharmacies given the shortage of pharmacists in the public health system. In a memorandum dated 2 July 2010, the Department of Health states, “There is no indication of any legislation prohibiting the supply of medicines for three months to any one patient. This practice should only be implemented once the patient has proved stable on the regimen.”